0IV3.LGeron Corporation

Über

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

www.geron.com

Kennzahlen

Marktkapitalisierung

853.83M

EPS

-0.13

Dividendenrendite

0.00%

Beta

0.60

KBV

3.98

EK-Rendite

-37.0%

Sektor

Healthcare

Branche

Biotechnology

CEO

Harout Semerjian

Mitarbeiter

258

IPO-Datum

2018-01-29

Land

US